Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5780)
  3. Review (420)
  4. Editorial (194)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13274)
  2. Center for Hematologic Malignancies (10609)
  3. GSK Faculty (4481)
  4. Adult Leukemia (3672)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2704)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (336)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (329)
  5. Haematologica (291)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1529)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic evolution and resistance during pirtobrutinib therapy in covalent btk-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: Updated analysis from the BRUIN study
    Meeting Abstract

    Brown, J. R.; Desikan, S. P.; Nguyen, B.; Won, H.; Tantawy, S. I.; McNeely, S.; Marella, N.; Ebata, K.; Woyach, J. A.; Patel, K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT)
    Meeting Abstract

    DiPersio, J.; Cooper, B. W.; Suh, H. C.; Koura, D.; Bernard, L.; Shah, N. N.; Walter, R. B.; Perales, M. A.; Mapara, M.; Tamari, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Response to mosunetuzumab in patients with B-cell lymphomas relapsed or refractory after CAR-T cell therapy is associated with changes in lymphocyte counts
    Meeting Abstract

    Chong, E. A.; Penuel, E.; Bartlett, N. L.; Bosch, F.; Budde, L. E.; Fay, K.; Flinn, I. W.; Goy, A.; Kumar, A.; Lundberg, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Loss of CCAAT-enhancer binding protein delta promotes acute myeloid leukemia cell proliferation and survival by upregulating cyclin D1 expression
    Meeting Abstract

    Prajapati, S.; Meydan, C.; Dillon, R.; Dunham, N.; Fan, H.; Gandara, J. A.; Lee, T.; Neelamraju, Y.; Wang, Z.; Zumbo, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HMGA1 chromatin regulators drive immune evasion in MPN progression through epigenetic rewiring to repress antigen presentation
    Meeting Abstract

    Kim, J.; Supreme, A. A.; West, B.; Antopia, M. C.; Reddy, K.; Cope, L.; Kim, J. H.; Rampal, R. K.; Koche, R.; Spivak, J. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Novel causal inference method estimates treatment effects of contemporary drugs in a global cohort of patients with relapsed and refractory mature T-cell and NK-cell neoplasms
    Meeting Abstract

    Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Sorial, M. N.; Eche-Ugwu, I. J.; Miranda, E.; Chiattone, C.; Stuver, R.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G. S.; Kim, H. T.; O'Connor, S.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; El-Jawahri, A.; McAfee, S.; Hem, J.; Lozano, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: Updated results from the phase 3 KarMMa-3 trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: Preliminary safety and efficacy results
    Meeting Abstract

    Falchi, L.; Jardin, F.; Haioun, C.; Wrobel, T.; Mészáros Joergensen, J.; Bastos-Oreiro, M.; Mou, E.; Martinez-Lopez, J.; Budde, L. E.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL
    Meeting Abstract

    Merryman, R. W.; Rhoades, J.; Xiong, K.; Antel, K.; An, H. H.; Redd, R. A.; McDonough, M. M.; Guerrero, L.; Crnjac, A.; Sridhar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save